Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register

Development programmes

A programme groups trials sharing a sponsor, a compound and a development plan. Records within a programme are reported together and their instalments are labelled.

§1Programmes in the register

Table 1. Development programmes, with the compound each concerns and the composition of its records.

ProgrammeCompoundPublished trialsProgramme recordsFirst record
ACHIEVE — orforglipron in type 2 diabetesOrforglipron272023
ADJUNCT — liraglutide as adjunct in type 1 diabetesLiraglutide282013
AMPLITUDE — efpeglenatideExenatide142018
ATTAIN — orforglipron in obesityOrforglipron232023
AWARD — dulaglutideDulaglutide5252010
DREAMS — mazdutide in Chinese populationsMazdutide352022
DURATION — exenatide extended releaseExenatide2102007
ELIXA — lixisenatide cardiovascular outcomesLixisenatide142010
ESSENCE — semaglutide in steatohepatitisSemaglutide132021
EXSCEL — exenatide extended release cardiovascular outcomesExenatide132010
FLOW — semaglutide in chronic kidney diseaseSemaglutide132019
GetGoal — lixisenatideLixisenatide3152008
GLORY — mazdutideMazdutide142022
Harmony Outcomes — albiglutideDulaglutide152015
LEADER — liraglutide cardiovascular outcomesLiraglutide142010
MariTide — maridebart cafraglutideMaridebart cafraglutide372021
MMPOWER — elamipretide (SS-31) in primary mitochondrial myopathySS-31 (elamipretide)272014
OASIS — oral semaglutide in obesitySemaglutide, oral132021
PIONEER — oral semaglutideSemaglutide, oral292016
RECONNECT — bremelanotide (PT-141)PT-141 (bremelanotide)292014
REDEFINE — cagrilintide with semaglutideCagriSema (cagrilintide with semaglutide)392022
REWIND — dulaglutide cardiovascular outcomesDulaglutide142011
SCALE — liraglutide 3.0 mgLiraglutide4192011
SELECT — semaglutide cardiovascular outcomes without diabetesSemaglutide112018
SOUL — oral semaglutide cardiovascular outcomesSemaglutide, oral142019
STEP — Semaglutide Treatment Effect in People with obesitySemaglutide9312018
STRIDE — semaglutide in peripheral arterial diseaseSemaglutide132020
SUMMIT — tirzepatide in heart failure with preserved ejection fractionTirzepatide152021
SURMOUNT — tirzepatide in obesityTirzepatide8182019
SURPASS — tirzepatide in type 2 diabetesTirzepatide6212018
SUSTAIN — semaglutide in type 2 diabetesSemaglutide3142013
SYNCHRONIZE — survodutideSurvodutide382023
TRIUMPH — retatrutideRetatrutide5122022
Compound Evidence Institute · CEI institutional document · https://compoundevidence.com/trials/programmes/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.